Pegipanermin - INmune Bio
Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTMLatest Information Update: 04 Jul 2025
At a glance
- Originator Emory University; Xencor
- Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
- Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
- Preclinical HER2 positive breast cancer
- No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
- Discontinued COVID-19 respiratory infection; Parkinson's disease
Most Recent Events
- 01 Jul 2025 Efficacy and adverse events data from a phase II MINDFuL trial in Alzheimer's disease released by INmune Bio
- 10 Jun 2025 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by INmune Bio
- 08 May 2025 INmune Bio plans a phase II trial for Major depressive disorder (Treatment-resistant) once NIH funding is available